OnCo

Niraparib maintenance

Checked 2026-09-09

Newly diagnosed advanced ovarian cancer after platinum response, regardless of BRCA status

One cycle

every 28 days × 3 · about 12 weeks in total
1781415212228Niraparib: 200 mg once daily if weight under 77 kg or platelets under 150 × 10⁹/L; otherwise 300 mg, OralNiraparib
28-day cycle × 3 years (PRIMA) or until progression (about 12 weeks)Oral Daily oral course

Components

DrugDoseRouteDays
Niraparib
Small-molecule PARP inhibitor
200 mg once daily if weight under 77 kg or platelets under 150 × 10⁹/L; otherwise 300 mgOralD1-28
Cycles
3 years (PRIMA) or until progression
28-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine

Notes

  • Individualised starting dose cut grade 3 thrombocytopenia from 48% to 21%.

Used in

Products

Source

PRIMA, NEJM 2019

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers